Nucala® (mepolizumab) – New indication
May 22, 2025, - GSK announced the FDA approval of Nucala (mepolizumab), for the add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
Download PDF
